Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Low response to antiviral therapy for recurrent liver graft infection with hepatitis C virus genotype 1B

J Ziółkowski, L Pączek, G Senatorski, D Porowski, K Zieniewicz, B Ziarkiewicz- Wróblewska, M Krawczyk

Ann Transplant 2009; 14(1): 28-28 :: ID: 880300


Background: Hepatitis C recurrence is a common complication after liver
transplantation and leads to liver failure and early graft loss. The aim of our  study was to evaluate effectiveness of treatment with pegylated interferon with ribavirin on virus C eradication. 30 patients with HCV recurrence were followed during the antiviral therapy and 12 months after the end of the treatment. There were 25 patients with HCV genotype 1b, one patient with genotype 3a. 4 patients' genotyping were not done. Before therapy, mean Fibrosis Score was 0.8, and mean Hepatitis Activity Index 6.5. 41% of patients discontinued therapy or have lowered the dose of medications, because of adverse events. By the end of the treatment, HCV negative were 10 patients (34%), after next 12 months HCV negative were only 3 of them (10%) (2 patients with genotype 1b, 1 patient with genotype 3a). Serum virus load was lower at the end of antiviral treatment compared to the pre-therapy load in 11 (60%) patients with persistent viraemia; however at the end of the follow-up virus load was lower only in 8 patients (30%). Liver biopsy (n=9) showed progression of fibrosis or hepatitis in patients which did not eradicate C virus, despite lowering the virus load during the antiviral treatment. In all 4 cases of re-therapy the HCV was not eradicated.
Conclusions: Antiviral treatment of HCV genotype 1b recurrence after liver
transplantation with pegylated interferon and ribavirin gives small percent
of eradication. There is no improvement in histological changes after antiviral treatment in a group of patients without eradication.

Keywords: Liver Transplantation

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358